Pentobarbital anesthetized dogs were subjected to 90 minutes of left circumflex coronary artery (LCCA) occlusion followed by 72 hours of reperfusion. Control or anti-Mol (904) F(ab')2 fragments of monoclonal antibodies were administered intravenously at a dose of 1 mg/kg beginning 45 minutes after occlusion and at a dose of 0.5 mg/kg at 12, 24, 36, and 48 hours after reperfusion. Myocardial infarct size expressed as a percentage of the area at risk (IN/AR) measured postmortem after 72 hours of reperfusion was significantly reduced by 904 F(ab')2 (21.6±2.8%, n=8) compared with control F(abl2 (37.4±5.8%, n=8; p<0.025). There were no significant differences between groups in heart rate, mean arterial blood pressure, ratepressure product, or LCCA blood flow that could account for a reduced infarct size. Regional myocardial blood flow (RMBF) was determined with 15 -,m radiolabeled microspheres. Transmural blood flows (ml/min/g) within the region of myocardium at risk were not statistically different between treatment groups. Infarct size in both groups was related to regional myocardial blood flow, and the relation was shifted downward in the group treated with the anti-Mol F(ab')2 antibody (analysis of covariance, p=0.01). Thus, anti-Mol F(ab')2 produces a sustained limitation of myocardial infarct size compared with controls under similar hemodynamic conditions and a similar degree of myocardial ischemia as determined by RMBF. These data suggest that inhibition of neutrophil adhesive interactions (as suggested by the inhibitory effect of anti-Mol on canine neutrophil aggregation) may be an effective mechanism for protection against myocardial injury secondary to myocardial ischemia and reperfusion. (Circulation 1990;81:226-237) It is now well recognized that the process of myocardial infarction with reperfusion of the previously ischemic myocardium involves components of a typical inflammatory reaction. There is elaboration of inflammatory mediators as well as infiltration of blood cells such as polymorphonuclear leukocytes (neutrophils).' Abundant evidence exists to indicate that neutrophil infiltration and activation in the previously ischemic region result in an exten-
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of adhesive (including inhibition of aggregation) interactions of neutrophils within the myocardium after reperfusion.
The results of a previous study9 suggested that by blocking neutrophil adhesive interactions, anti-Mol could be useful as a therapeutic agent to reduce myocardial infarct size. However, several questions remained unanswered: Can anti-Mol administration provide for effective myocardial protection after a longer period of reperfusion (e.g., 72 hours)? Does the apparent beneficial effect of anti-Mol occur because of a specific blockade of Molmediated adhesive interactions or because of nonspecific Fc receptor-mediated clearance of activated neutrophils from the circulation? Thus, the present study was undertaken to determine whether the administration of a F(ab')2 fragment of antiMol could reduce the extent of myocardial ischemiareperfusion injury that results when the acute inflammatory response is fully expressed (72 hours). The data provide additional evidence to support the concept that an alteration in neutrophil function can effectively reduce the extent of tissue injury associated with myocardial reperfusion.
Methods Materials
The generation of the murine IgG, monoclonal antibodies (anti-Mol, clone 904, and control antibodies) has been described previously.915 The anti-Mol antibody binds to an epitope on the CD11b, 155-kD a-polypeptide of the Mol glycoprotein expressed by human15 and dog9"18 neutrophils. The control antibody was raised against the idiotype determinant of a T-cell receptor expressed by a human T-cell hybridoma. Thus, it displays no reactivity with human or canine cells. Sterile, pyrogen-free F(ab')2 fragments prepared by pepsin digestion of whole antibody and purified by chromatographic techniques were supplied by Coulter Immunology (Hialeah, Florida). All other reagents were supplied by Sigma Chemical (St. Louis, Missouri) unless otherwise noted.
Surgical Preparation
Adult male, mongrel dogs (12-17 kg) were anesthetized with 30 mg/kg sodium pentobarbital and ventilated with room air (tidal volume, 30 ml/kg at a rate of 12/min). Aseptic surgical methods were used. A left thoracotomy was performed, and the proximal left circumflex coronary artery (LCCA) was isolated and instrumented for continuous blood flow measurement with a calibrated electromagnetic flow probe.
Arterial blood pressure, heart rate, the standard limb lead II electrocardiogram, and LCCA blood flow were recorded continuously. Regional myocardial ischemia was produced by occluding the LCCA for 90 minutes followed by reperfusion (see protocol scheme, Figure 1) 
Deternination of Regional Myocardial Blood Flow
Regional myocardial blood flows were determined at three time points during each experiment (before occlusion, 5 minutes after occlusion, and 80 minutes after occlusion) with tracer-labeled microspheres (15- gm diameter, New England Nuclear) by the reference withdrawal method24 as previously described. 6 Injections of microspheres (labeled with cerium 141, ruthenium 103, or scandium 46) were made in each experiment, with the order of the isotopes randomized. Each bottle of microspheres was placed in an ultrasonic bath with subsequent vortex agitation before injection to ensure that adequate dispersal of the microsphere suspensions was achieved before being administered. Reference arterial blood samples were obtained simultaneously from both the femoral and carotid arteries beginning immediately before the injection of microspheres into the left atrium and ending 2 minutes later. The reference sample counts were averaged for calculation of myocardial blood flow. If the reference sample counts varied by more than 15%, the data were discarded.
Tissue samples weighing 0.5-1.0 g were dissected from the subepicardium, midmyocardium, and subendocardium of the perfusion bed supplied by the LCCA and from the nonischemic region. At least three sections from each heart were used so that blood flows to each region represent the average of three or four samples for each experiment. Regional myocardial blood flow was calculated by the formula: Qm= Qrx Cm/Cr where Qm is myocardial blood flow (ml/min), Qr is reference blood flow (ml/min), Cm In addition to this semi-quantitative assessment of circulating F(ab')2 concentrations, the detection of immunologically active 904 F(ab')2 was assayed by indirect immunofluorescence analysis in which 106 Mol-positive test cells (calcium ionophore A23187-stimulated human neutrophils28) were incubated with dog serum ('/2 final dilution) for 30 minutes at 40 C. After washing in buffer containing a saturating concentration of fluorescein-conjugated goat anti-mouse Ig (Coulter Immunology) for an additional 30 minutes at 4°C, antibody binding to test cells was quantitated by flow cytometric analysis as described previously.9 Relative F(ab')2 reactivity (%) in serum samples was determined by comparing the mean channel fluorescence intensity (linear scale) of 5,000 test cells exposed to serum samples relative with the mean channel fluorescence intensity of cells exposed to a saturating quantity of 904 F(ab')2. Ex Vivo Analysis of Neutrophil-904 Binding by Flow Cytometry
Neutrophils from the blood of each animal were isolated before the initial bolus infusion of 904 (t=0) or control antibody and then at 1, 24, 48, and 72 hours thereafter (including both preadministration and postadministration of additional bolus infusions of 904 or control (F(ab')2) given at 24 and 48 hours). In this analysis, we isolated a leukocyte-enriched fraction of EDTA-anticoagulated whole blood by ammonium chloride lysis of erythrocytes and then subjected these cells to immunofluorescence staining for any bound 904 by a 30-minute incubation with FITC-labeled goat anti-mouse Ig (which detects the binding of 904 to activated human or dog PMNs). When the postinfusion samples were compared with neutrophils obtained before the initial 904 infusion (a suitable negative control baseline), there was minimal and variable staining above background (an observation consistent with the variable degree of intact IgG bound to the PMNs of 904-treated dogs in our earlier study9). Evaluation of Neutrophil Accumulation in Myocardial Tissue: Myeloperoxidase (MPO) Assay and Histology Samples of myocardium (50-200 mg) were taken from the central infarct region, the noninfarcted tissue within the area at risk, the endocardial to epicardial border zone between infarct region and area at risk, and normal noninfarcted and unstained myocardium. The tissue samples were homogenized and assayed for MPO content as described by Bradley and coworkers. 29 The assays involve the extraction of MPO by homogenizing (Polytron) the tissue in buffer containing 50 mM phosphate with 0.5% hexadecyltrimethylammonium bromide and 5 mM EDTA (pH 6.0). After two freeze-thaw cycles and sonication, the samples were then centrifuged, and the supernatants were assayed in 50 mM phosphate (pH 6.0) with 0.167 mg/ml O-dianisidine and 0.0005% hydrogen peroxide. The rate of decomposition of hydrogen peroxide by MPO was determined by measuring the change in absorbance at 460 nm. One unit of MPO activity is defined as the amount of enzyme that decomposes 1 ,umol/min hydrogen peroxide at 250 C under the conditions of the assay. The myocardial content of MPO activity has been correlated with histologic evidence of neutrophil infiltration. [6] [7] [8] 30 Histologic assessment of neutrophil accumulation was performed in a blinded fashion separately by two pathologists (J.C.F. and K.A.R.) on hematoxylin and eosin-stained sections from the myocardium in the region of infarcted myocardium and at the border region between infarcted and uninfarcted tissue. A relative infiltration score of 0 to 4 was assigned to each heart based on the presence of neutrophil and monocyte infiltration.
Neutrophil Aggregation
Aggregation of neutrophils was performed as previously described.18 Briefly, canine neutrophils were isolated from citrated venous blood by ficoll-hypaque gradient separation followed by dextran gravity sedimentation. Erythrocytes were lysed with hypotonic (0.27%) sodium chloride. Neutrophils were then resuspended in Hank's balanced salt solution (107 neutrophils/ml) and allowed to equilibrate 1 minute at 370 C in aggregation cuvettes. Aggregation was induced with the addition of phorbol myristate acetate (PMA) (125 ng/ml) and was recorded as a percent change in light transmittance by a platelet aggregometer. Control F(ab')2 (117 ,ug/ml final concentration), 904 F(ab')2 (105 ,g/ml final), or intact 904 monoclonal antibody (100 ,ug/ml final) was preincubated with the neutrophil suspension for 1 minute before the addition of the PMA. Exclusion Criteria
To ensure that all treatment groups were comparable with respect to the degree of regional myocardial ischemia, predetermined exclusion criteria were established. Animals were excluded from the final data analysis if they manifested failure to demonstrate electrocardiographic signs of regional ischemia (i.e., <0.1 mV ST-segment change on coronary occlusion), ventricular fibrillation that was not converted with fewer than four attempts at low-amperage DC defibrillation (<30 J applied directly to the heart surface), or the presence of heartworms postmortem.
Statistical Analyses
All data are expressed as mean+1 SEM. Data were compared between treatment groups by Student's t test (one-tailed). The evaluation of the data from histologic sections pertaining to neutrophil accumulation was tested with Wilcoxon's two-sample rank-sum test (Mann-Whitney test).31 All other data were compared with a respective control group by Student's t test using Bonferroni's method to control for experimental a-error when making multiple comparisons with the same control group.
The size of the myocardial risk region and the degree of collateral blood flow are two important determinants in the extent of ischemic myocardial injury and tissue necrosis. Infarct size was assessed in relation to collateral blood flow measured in the outer two thirds of the central ischemic zone. An analysis of covariance was performed in which collateral blood flow was the independent variable with the object of determining whether there existed a statistically significant difference in the calculated infarct size between the two groups when the influence of collateral blood flow was controlled.
Results
Twenty-six dogs were used in this study comparing the effects of 904 monoclonal F(ab')2 and control monoclonal F(ab')2 on the size of myocardial infarct that develops after 90 minutes of ischemia and 72 hours of reperfusion. A total of 10 dogs was excluded from the final data analysis because one dog died due to ventricular fibrillation during coronary occlusion before treatment with antibody, two dogs were excluded because of failure to develop objective signs of ischemia during coronary occlusion, and seven dogs died because of ventricular fibrillation that was not converted with fewer than four attempts at low-energy cardioversion (<30 J with internal paddles) (three control dogs, three dogs that were treated with 904, and one that died before treatment with antibody). In addition, one dog that had been treated with 904 died during the first night, presumably due 108±7  152+9  153±7  175±18  188±17  0  0  30  101+6  109+8  153+9  153+9  179+17  194±19  0  0  60  106+5  109+8  153+10  159+7  183+16  199±21  0  0  90  105+6  111+7  159+10  160+8  192+16  208+18  0  0  Reperfusion (min)  15  100±6  108+7  164±+10  157±9  196+21  198+20  23+3  25+4   30  97+3  99+7  171+10  154+9  194±14  180+16  22±1  29±4  60  102±5  103+7  157+11  157+9  186+18  191±18  18±1t (Figure 3 ). There was a good correlation between the severity of the ischemia as determined by regional myocardial blood flow and the infarct size that eventually developed (r=0.84). In contrast, for a given severity of ischemia, the infarct size was smaller in the 904-treatment group than in the control group (r=0.46). Using an analysis of covariance in which the mean collateral blood flow to the outer two thirds of the ischemic myocardium was a covariate, infarct size expressed as a percentage of the area at risk was smaller for the anti-Mol (904) F(ab')2 monoclonal antibody treatment group (F ratio=9.751; p =0.008). The protective effect of the anti-Mol treatment was not due to a difference in ischemic collateral blood flow or to an increase in collateral blood flow to the ischemic myocardium.
Circulating Neutrophil Counts
There were no differences between the two treatment groups in circulating neutrophil counts at baseline (0 hours; Figure 4) . When determined at 6, 24, 48, and 72 hours after the initial antibody administration, the neutrophil counts were similar between groups and showed the expected increase over baseline values. Myocardial MPO Content Three myocardial regions were assayed for myeloperoxidase activity as an indicator of neutrophil accumulation (Table 4 ). There were no significant differences between the two groups in MPO in any of the three myocardial regions (center of infarct, noninfarcted myocardium within the risk region, or tissue that lies between the infarcted and noninfarcted tissue within the area at risk).
Histologic Assessment
There were no differences between the two treatment groups in the accumulation of inflammatory cells (neutrophils and monocytes) as observed with hematoxylin and eosin staining of midventricular transmural sections through the central infarcted region. When graded in a blinded fashion from 0 to 4+, the control group was 2.5+0.5 (mean+SEM) and the anti-Mol group was 2.1+0.8 ( Figure 5) . These values were not significantly different when compared with the Wilcoxon rank-sum test. Serum F(ab')2 Concentrations Determined by ELISA Serum F(ab')2 concentrations were determined for each dog in both treatment groups as an indication of circulating antibody excess (Table 5) . Baseline values for F(ab')2 concentrations in animals (before antibody administration) were below detectable limits (<0.019 ,g/ml). Antibody concentrations during the course of the 72 hours of reperfusion indicate that there is circulating antibody excess in the blood in most dogs during the initial 48 hours after reperfusion.
Serum F(ab')2 Concentration Determined by Flow Cytometry
In addition to determining serum antibody concentration by ELISA, serum samples were allowed to >20  >20  >20  >20  >20  >20  >20  >20  >20  >20  21 tValues represent samples taken before injection of F(ab')2. §Values represent samples taken 10 minutes after injection of F(ab')2.
react with calcium ionophore stimulated human neutrophils. In this manner, the relative quantity of immunologically reactive antibody was measured in the group of dogs that received anti-Mol F(ab')2 ( Figure 6 ). Mean serum F(ab')2 concentrations, normalized to 100% reactivity for the serum sample that was drawn 5 minutes after the initial antibody administration, were significantly elevated during the first 6 hours and again after each antibody injection (12, transmittance with a platelet aggregometer. For each preparation of neutrophils, the amount of change in light transmittance when cells were activated with 125 ng/ml PMA was considered 100%. The results were then expressed as a percent of maximal possible aggregation. The control F(ab')2 did not inhibit PMA induced aggregation (91.8±7.6%, n=6, Figure 7 ). The anti-Mol F(ab')2 (904) inhibited aggregation to 36.3 ±3.6% (n=4; p<0.0005, compared with control F(ab')2). The intact anti-Mol antibody (whole 904) limited aggregation to only 11.3±4.5% of PMAinduced aggregation (n =3; p<0.0005 compared with control F(ab')2). The n values in parentheses indicate the number of separate preparations of canine neutrophils. Assays for each n were run in triplicate or duplicate and averaged. Thus, both the intact antiMol and the F(ab')2 anti-Mol were effective inhibitors of canine neutrophil aggregation in vitro. Discussion The present study reports evidence that ultimate myocardial infarct size can be reduced with the intravenous administration of F(ab')2 fragments of a monoclonal antibody directed against the leukocyte adhesion-promoting molecule Mol (CD1 lb/CD118).
In a previous study from this laboratory, the intact monoclonal antibody (904) limited the development of myocardial necrosis after 90 minutes of coronary artery occlusion and a short period (6 hours) of reperfusion.9 The present study confirms and extends these observations to show that F(ab')2 fragments were as effective as the whole antibody and protection was observed after a prolonged period of reperfusion (72 hours). The data on neutrophil accumulation in the myocardium from the present study that used two separate techniques (histology, Figure 5 ; and myeloperoxidase activity in myocardium Table 4 ) may indicate that there was no attenuation of inflammatory cell infiltration. However, whereas MPO activity is an acceptable indicator of neutrophil content after short periods of reperfusion,5'6'8'29 neutrophil autolysis and autooxidation of MPO at the inflammatory site may obscure differences in neutrophil accumulation after longer periods of reperfusion51,52 (e.g., 72 hours). These data are consistent with our earlier observations with the administration of iloprost in the same animal model of myocardial infarction: Iloprost reduced infarct size and neutrophil accumulation when canine hearts were reperfused for 6 hours and then examined after sacrifice, but after 72 hours of reperfusion (in which iloprost still limited infarct size),19 measurements of MPO activity in heart muscle and histologic assessment indicated that the neutrophil influx had resolved. The resolution of the acute inflammatory process by 72 hours of reperfusion was also observed by Reimer and coworkers.53 Nonetheless, it is possible that anti-Mol (904) may be protecting without reducing the accumulation of neutrophils in the heart.
The increase in circulating neutrophil counts (Figure 4) that accompanies the development of a myocardial infarct in this study is similar to previous reports.19,54 Several interesting observations can be made with respect to neutrophil counts. First, the circulating neutrophil counts did not decrease significantly when exposed to the anti-Mol F(ab')2, indicating that the antibody-bound neutrophils are not being cleared from the circulation. Second, the antiMol F(ab')2 did not prevent the leukocytosis that accompanies the inflammatory reaction to surgical intervention and acute myocardial infarction. This is to be expected because humans who have a genetic deficiency in the Mol glycoprotein expression have defects in leukocyte adhesion and demonstrate a persistent elevation in circulating leukocyte counts. 55 Because both groups of dogs developed similar degrees of myocardial ischemia when measured by regional myocardial blood flow (Table 3 and Figure  3 ), the mechanism of protection can not be attributed to baseline differences in regional blood flow or to an increase in collateral blood flow to the ischemic region. In addition, there were no differences in hemodynamics that could have accounted for a myocardial protective effect. Thus, the myocardial protection evidenced in these experiments is best explained by the effect of anti-Mol antibody on neutrophil function.
In conclusion, the administration of F(ab')2 fragments of the monoclonal antibody directed against Mol significantly limits the extent of myocardial injury that results after 72 hours of reperfusion. The results indicate that inhibition of leukocyte adhesion, aggregation, or oxidant production by anti-Mol antibodies may prove to be useful adjunctive therapy in conjunction with thrombolysis or angioplasty in reducing the amount of myocardium that becomes irreversibly injured after reperfusion.
